GlassScriptPhysician profile
Debra D Powell
NPI 1184677395
$12,100.60
in general payments reported to CMS, 2019-2025
29 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $973 · 2022: $5,535 · 2023: $2,245 · 2024: $1,988 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,332 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,332.40 |
| Education | $260.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,548.90 | 2021-2025 | |
| Janssen Biotech, INC. | $983.95 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $931.81 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Pfizer INC. | $529.79 | 2021-2025 | |
| Hill Dermaceuticals, INC. | $495.22 | 2023 | Tolak |
| Lilly USA, LLC | $491.55 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $418.77 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $391.80 | 2021-2025 | |
| Dermavant Sciences, INC. | $357.97 | 2023-2024 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $357.83 | 2022-2025 | Clindacin Etz, Neuac, Neo-Synalar |
| Amgen INC. | $273.01 | 2021-2025 | Otezla, Enbrel, Otezla |
| Leo Pharma INC. | $206.91 | 2021-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $200.28 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.96 | 2021-2024 | Cabtreo, Jublia |
| Regeneron Healthcare Solutions, INC. | $107.01 | 2023-2025 | Dupixent, Libtayo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $102.44 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $88.74 | 2023-2024 | Zoryve |
| Janssen Scientific Affairs, LLC | $85.60 | 2022 | |
| Organon LLC | $75.38 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.23 | 2023-2024 | Spevigo, Cyltezo |
| Incyte Corporation | $60.27 | 2022-2023 | Opzelura |
| Galderma Laboratories, L.P. | $39.96 | 2021-2022 | |
| Almirall LLC | $38.23 | 2021-2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $37.18 | 2021 | |
| Ucb, INC. | $24.23 | 2021 | |
| Allergan, INC. | $24.22 | 2021 | |
| Strata Skin Sciences, INC. | $23.64 | 2025 | Xtrac |
| Biofrontera INC. | $20.73 | 2022 | |
| Botanix Sb INC | $13.99 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.